<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880746</url>
  </required_header>
  <id_info>
    <org_study_id>ASCT-001</org_study_id>
    <nct_id>NCT04880746</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study</brief_title>
  <official_title>Efficacy and Safety of Cladribine Combined With BEAC ( Semustine, Etoposide, Cytarabine, Cyclophosphamide) Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Hematology and Oncology Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Zhongshan Hospital of Dalian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center clinical study will evaluate the efficacy and safety of Cladribine Combined&#xD;
      With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral T-cell lymphomas (PTCL) is a group of highly heterogeneous aggressive non-Hodgkin&#xD;
      lymphomas originating from mature post-thymic T lymphocytes or NK/T cells. The treatment&#xD;
      effect of patients receiving autologous hematopoietic stem cell transplantation (ASCT) is&#xD;
      better than traditional chemotherapy, but the recurrence after transplantation is still as&#xD;
      high as 50%. It is an urgent clinical problem to reduce the recurrence after PTCL&#xD;
      transplantation. Cladribine can kill quiescent tumor cells, which is the main reason of tumor&#xD;
      recurrence. Since 2018, our center has used cladribine combined with BEAC pretreatment&#xD;
      regimen to treat 20 patients with PTCL. The PFS reached 68% at 2 years, which is about 15%&#xD;
      higher than the previous classic BEAC regimen. This multi-center clinical study will further&#xD;
      evaluate the efficacy and safety of Cladribine combined with BEAC pretreatment regimen in the&#xD;
      Treatment of Peripheral T-cell Lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2020</start_date>
  <completion_date type="Anticipated">October 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 2 years)</time_frame>
    <description>Progression-free survival was defined as the time from the date of ASCT until the date of the first documented day of disease progression or relapse, using Revised Standards for Efficacy Evaluation of Malignant Lymphoma in 2007, or death from any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 2 years)</time_frame>
    <description>Overall survival was defined as the time from the date of ASCT to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall remission rate</measure>
    <time_frame>3 months after the transplantation</time_frame>
    <description>Percentage of participants with overall response was determined on the basis of Revised Standards for Efficacy Evaluation of Malignant Lymphoma in 2007.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplantation-related adverse reactions</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 5 years)</time_frame>
    <description>Transplantation-related adverse reactions are any untoward medical occurrence in a participant which is related to ASCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient tolerance</measure>
    <time_frame>Through the whole course of ASCT, an average of one month</time_frame>
    <description>Percentage of participants who can tolerate the whole treatment of ASCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 5 years)</time_frame>
    <description>Percentage of participants who relapse determined on the basis of Revised Standards for Efficacy Evaluation of Malignant Lymphoma in 2007.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>BEAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine combined with BEAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive Cladribine combined with BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEAC</intervention_name>
    <description>Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d</description>
    <arm_group_label>BEAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine combined with BEAC</intervention_name>
    <description>Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d</description>
    <arm_group_label>Cladribine combined with BEAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years old, no gender limit;&#xD;
&#xD;
          -  ECOG 0-2, estimated survival time ≥ 3 months;&#xD;
&#xD;
          -  Pathologically newly diagnosed with PTCL (except ALK+ anaplastic large cell lymphoma),&#xD;
             with PR or CR after 6 cycles of induction chemotherapy;&#xD;
&#xD;
          -  Hb≥80g/L, ANC≥1.0×10^9/L, PLT≥75×10^9/L; TBIL≤1.5×ULN, ALT/AST≤2.0× ULN, Cr ≤1.5×ULN&#xD;
             in the 14 days before enrollment&#xD;
&#xD;
          -  Have not received hematopoietic stem cell transplantation and other treatments within&#xD;
             4 weeks before enrollment;&#xD;
&#xD;
          -  The number of hematopoietic stem cells requires MNC ≥3×10^8/kg and/or CD34 cells&#xD;
             ≥2×10^6/kg;&#xD;
&#xD;
          -  Informed consented&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Accompanied by severe cardiac insufficiency, cardiac ejection fraction &lt;60%; or severe&#xD;
             arrhythmia, intolerance of pretreatment;&#xD;
&#xD;
          -  Accompanied by severe pulmonary insufficiency (obstructive and or restrictive&#xD;
             ventilatory disorders), intolerance of pretreatment;&#xD;
&#xD;
          -  Accompanied by severe liver function impairment, liver function indexes (ALT, TBIL)&#xD;
             are more than 3 times higher than the upper limit of normal, intolerance of&#xD;
             pretreatment;&#xD;
&#xD;
          -  Accompanied by severe renal insufficiency, the renal function index (Cr) is more than&#xD;
             2 times the upper limit of normal; or the 24-hour urine creatinine clearance rate Ccr&#xD;
             is less than 50ml/min, intolerance of pretreatment;&#xD;
&#xD;
          -  Severe active infection before transplantation, intolerance of pretreatment;&#xD;
&#xD;
          -  Accompanied by brain dysfunction or severe mental illness, unable to understand or&#xD;
             follow the research plan;&#xD;
&#xD;
          -  Pregnant or lactation；&#xD;
&#xD;
          -  Accompanied by other malignant tumors in need of treatment;&#xD;
&#xD;
          -  Patients who cannot guarantee the completion of the necessary treatment plan and&#xD;
             follow-up observation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao</last_name>
    <role>Study Chair</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weili Zhao</last_name>
    <phone>+862164370045</phone>
    <email>zwl_trial@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengpeng Xu</last_name>
    <phone>+862164370045</phone>
    <email>pengpeng_xu@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Zhao</last_name>
      <phone>+862164370045</phone>
      <email>zwl_trial@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 9, 2021</last_update_submitted>
  <last_update_submitted_qc>May 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>First Deputy Director, Hematology Department</investigator_title>
  </responsible_party>
  <keyword>Peripheral T-cell lymphoma</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>Cladribine</keyword>
  <keyword>BEAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

